{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:48Z","timestamp":1761863448047},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","gastro.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.gtc.2015.07.009","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:23:23Z","timestamp":1439252603000},"page":"845-857","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatitis C Virus"],"prefix":"10.1016","volume":"44","author":[{"given":"Javier","family":"Ampuero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2015.07.009_bib1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.009_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2893.2002.00319.x","article-title":"Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users","volume":"9","author":"Bourli\u00e8re","year":"2002","journal-title":"J\u00a0Viral Hepat"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2015.07.009_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.12711","article-title":"Optimal therapy of genotype-2 chronic hepatitis C: what's new?","volume":"35","author":"Bourli\u00e8re","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.gtc.2015.07.009_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/13543784.2013.775246","article-title":"Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection","volume":"22","author":"Herbst","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.gtc.2015.07.009_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gtc.2015.07.009_bib7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543784.2013.826189","article-title":"NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection","volume":"22","author":"Herbst","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.gtc.2015.07.009_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2014.10.007","article-title":"Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection","volume":"148","author":"Dore","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2015.07.009_bib9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","article-title":"Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2\u20136: TMC435-C202, a phase IIa, open-label study","volume":"56","author":"Moreno","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib10","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2015.07.009_bib11","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2015.07.009_bib12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2015.07.009_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2015.07.009_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial","volume":"21","author":"Omata","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gtc.2015.07.009_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2015.07.009_bib16","first-page":"197","article-title":"Exploratory trial of ombitasvir and ABT-450\/r with or without ribavirin for HCV genotype 1, 2, and 3 infection","volume":"70","author":"Lawitz","year":"2015","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.gtc.2015.07.009_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"HCV genotype 3 \u2013 the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.07.009_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3","volume":"33","author":"Rubbia-Brandt","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1665-2681(19)30842-7","article-title":"PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C","volume":"13","author":"Ampuero","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib22","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data","volume":"130","author":"Leandro","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2015.07.009_bib23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gtc.2015.07.009_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/gene.2015.14","article-title":"Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection","volume":"16","author":"Ampuero","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.gtc.2015.07.009_bib25","first-page":"1","article-title":"Sofosbuvir\u00a0+ peginterferon\/ribavirin for 12 weeks vs sofosbuvir\u00a0+ ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study","volume":"S1","author":"Foster","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.009_bib27","doi-asserted-by":"crossref","first-page":"S904","DOI":"10.1016\/S0016-5085(14)63289-3","article-title":"Sofosbuvir\/ledipasvir fixed dose combination is safe and effective in HCV infected populations including decompensated patients and patients with prior sofosbuvir treatment experience","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2015.07.009_bib28","first-page":"1045","article-title":"Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the Electron2 study","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.009_bib29","first-page":"1042","article-title":"High efficacy of LDV\/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.009_bib30","first-page":"1045","article-title":"High efficacy of treatment with sofosbuvir\u00a0+ GS-5816 \u00b1 ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection","volume":"60","author":"Pianko","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.009_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.gtc.2015.07.009_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 Infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2015.07.009_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jhep.2014.03.039","article-title":"IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2\/3 infection","volume":"61","author":"Eslam","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.009_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","article-title":"Treatment of hepatitis C in difficult-to-treat patients","volume":"12","author":"Ferenci","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib36","doi-asserted-by":"crossref","first-page":"e0122613","DOI":"10.1371\/journal.pone.0122613","article-title":"Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study","volume":"10","author":"Romero-G\u00f3mez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.gtc.2015.07.009_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1128\/JCM.02093-14","article-title":"High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods","volume":"53","author":"Quer","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.gtc.2015.07.009_bib38","series-title":"Harvoni (ledipasvir\/sofosbuvir) prescribing information","year":"2014"},{"key":"10.1016\/j.gtc.2015.07.009_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jhep.2013.07.014","article-title":"Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations","volume":"59","author":"Romero-G\u00f3mez","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.009_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.009_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cid\/ciu265","article-title":"Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks","volume":"59","author":"Abraham","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985531500076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985531500076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T02:44:15Z","timestamp":1567046655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985531500076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S088985531500076X"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2015.07.009","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Virus","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2015.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}